Autolus Therapeutics Plc ADR (AUTL) Stock Price, Quote & News

Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 3829 6230

Website: www.autolus.com

Address:

The Mediaworks, 191 Wood Lane White City, London, United Kingdom

PenkeTrading Jun. 26 at 3:13 PM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Autolus Therapeutics Ltd. Is that bullish or bearish? $AUTL #Autolus #RsiOverbought #NASDAQ

0 · Reply

gandolf63 Jun. 26 at 1:21 PM

$AUTL I think some of these funds are just like an impatient traitor always looking for another quick buck. I just think this is a great company with potential buyout by a bigger Pharma.

1 · Reply

TricksterT Jun. 26 at 1:13 PM

Needham Reiterates a Buy Rating on Autolus Therapeutics (AUTL), Keeps the PT at $10 $AUTL https://www.insidermonkey.com/blog/needham-reiterates-a-buy-rating-on-autolus-therapeutics-autl-keeps-the-pt-at-10-1556654/

0 · Reply

gandolf63 Jun. 26 at 12:53 PM

$AUTL this is not going to be easy. Some funds are buying in big and others are shedding their positions or whatever reason. It’s going to be a constant Aunt up and down as long as the pattern keeps shooting up. I don’t mind.

1 · Reply

TricksterT Jun. 26 at 12:32 PM

$AUTL don’t shoot the messenger but this is what my crystal ball is telling me.

0 · Reply

BRLondon Jun. 26 at 7:14 AM

$AUTL Strong entry by MAK Capital, they acquired 5.8% of the shares. They are a hedge fund, bargain hunters. Not the biggest name in the industry but decent.

1 · Reply

gandolf63 Jun. 26 at 3:31 AM

$AUTL

1 · Reply

RonIsWrong Jun. 25 at 11:11 PM

$AUTL MAK Capital takes a 15.4M share position

2 · Reply

PickemLowSellHigh Jun. 25 at 11:04 PM

$AUTL 2025-06-25 13G MAK CAPITAL FUND LP 15,408,638

1 · Reply

Holy_Xerxes Jun. 25 at 10:27 AM

$AUTL AHHHHHHH

0 · Reply

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Jun 6, 2025, 11:09 AM EDT - 20 days ago

Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market

May 29, 2025, 4:05 PM EDT - 27 days ago

Autolus Therapeutics to Participate in Upcoming Investor Conferences

$Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

May 23, 2025, 8:30 AM EDT - 4 weeks ago

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

May 20, 2025, 5:47 AM EDT - 5 weeks ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC CAPR CLPT EDIT NTLA VANI VERV

May 14, 2025, 9:30 AM EDT - 6 weeks ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

May 11, 2025, 4:22 AM EDT - 6 weeks ago

Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 7 weeks ago

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

$Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)$

Apr 25, 2025, 12:06 PM EDT - 2 months ago

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Apr 23, 2025, 4:05 PM EDT - 2 months ago

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Apr 22, 2025, 7:00 AM EDT - 2 months ago

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 2, 2025, 7:00 AM EDT - 3 months ago

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:00 AM EDT - 3 months ago

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Mar 20, 2025, 11:55 AM EDT - 3 months ago

Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call Transcript

Mar 20, 2025, 7:00 AM EDT - 3 months ago

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 6, 2025, 7:00 AM EST - 4 months ago

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Mar 4, 2025, 10:21 AM EST - 4 months ago

Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy

Jan 17, 2025, 7:00 AM EST - 5 months ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Dec 9, 2024, 7:30 PM EST - 7 months ago

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Nov 21, 2024, 12:16 AM EST - 7 months ago

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market

Nov 12, 2024, 2:57 PM EST - 8 months ago

Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript

$Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)$

Nov 8, 2024, 4:23 PM EST - 8 months ago

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Oct 28, 2024, 5:00 PM EDT - 8 months ago

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Sep 6, 2024, 2:12 PM EDT - 10 months ago

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case

Aug 10, 2024, 12:05 AM EDT - 11 months ago

Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript

Jul 26, 2024, 7:00 AM EDT - 11 months ago

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

$Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress$

Jun 14, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

May 31, 2024, 8:00 AM EDT - 1 year ago

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

May 17, 2024, 12:55 PM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript

May 17, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 14, 2024, 1:02 PM EDT - 1 year ago

Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity

Apr 24, 2024, 10:00 AM EDT - 1 year ago

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Announces Changes to its Board of Directors

Mar 15, 2024, 5:23 AM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Mar 12, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

Feb 29, 2024, 7:00 AM EST - 1 year ago

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

Feb 8, 2024, 7:00 AM EST - 1 year ago

Autolus Announces Pricing of Underwritten Offering

Feb 8, 2024, 5:45 AM EST - 1 year ago

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

Feb 6, 2024, 9:52 AM EST - 1 year ago

Autolus Upgrades Leadership And Faces CAR-T Approval

Jan 23, 2024, 7:00 AM EST - 1 year ago

Autolus Therapeutics announces publication in ACS Chemical Biology

$Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)$

Jan 22, 2024, 7:00 AM EST - 1 year ago

Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)

Dec 18, 2023, 4:12 AM EST - 1 year ago

Autolus Therapeutics: Pivotal Trial Using Familiar Approach, Possible Approval Coming Fast

Dec 9, 2023, 8:30 PM EST - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

$Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)$

Nov 27, 2023, 7:00 AM EST - 1 year ago

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)

Nov 15, 2023, 7:00 AM EST - 1 year ago

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

Nov 6, 2023, 7:00 AM EST - 1 year ago

Autolus Therapeutics announces participation in upcoming conferences

Nov 3, 2023, 10:05 PM EDT - 1 year ago

Autolus Therapeutics plc (AUTL) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 7:11 AM EDT - 1 year ago

Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

PenkeTrading Jun. 26 at 3:13 PM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Autolus Therapeutics Ltd. Is that bullish or bearish? $AUTL #Autolus #RsiOverbought #NASDAQ

0 · Reply

gandolf63 Jun. 26 at 1:21 PM

$AUTL I think some of these funds are just like an impatient traitor always looking for another quick buck. I just think this is a great company with potential buyout by a bigger Pharma.

1 · Reply

TricksterT Jun. 26 at 1:13 PM

0 · Reply

gandolf63 Jun. 26 at 12:53 PM

1 · Reply

TricksterT Jun. 26 at 12:32 PM

$AUTL don’t shoot the messenger but this is what my crystal ball is telling me.

0 · Reply

BRLondon Jun. 26 at 7:14 AM

$AUTL Strong entry by MAK Capital, they acquired 5.8% of the shares. They are a hedge fund, bargain hunters. Not the biggest name in the industry but decent.

1 · Reply

gandolf63 Jun. 26 at 3:31 AM

$AUTL

1 · Reply

RonIsWrong Jun. 25 at 11:11 PM

$AUTL MAK Capital takes a 15.4M share position

2 · Reply

PickemLowSellHigh Jun. 25 at 11:04 PM

$AUTL 2025-06-25 13G MAK CAPITAL FUND LP 15,408,638

1 · Reply

Holy_Xerxes Jun. 25 at 10:27 AM

$AUTL AHHHHHHH

0 · Reply

RonIsWrong Jun. 25 at 2:33 AM

$AUTL

3 · Reply

ians Jun. 24 at 5:22 PM

$AUTL Obe-cel’s durability of response increases with 50% of r/r B-ALL pts. In remission at 24mo after 33mo median follow-up. 👏 Perhaps 1/2L indication should be considered? Then that rev & earnings growth trajectory will definitely take off. $9-11 LT PT🚀☘️💎 https://finance.yahoo.com/news/ardelyx-leads-pack-3-promising-120501596.html

1 · Reply

Omnivest Jun. 24 at 2:09 AM

$AUTL That bounce off the $2.03 is a good sign. Look at the YTD. I like what I see. Just need some news and decent volume to send it. News is coming. Just have to be patient. Things are about to get exciting in here. Just glad to be early to the party!

1 · Reply

BRLondon Jun. 23 at 9:12 PM

$AUTL something's cooking here, no one sells under 2. Time for next leg up to 3. I may regret not getting more shares, I was waiting for 1.70 pullback but I'm OK if it doesn't happen.

1 · Reply